Literature DB >> 25063320

Clinical management of paragangliomas.

Eleonora P Corssmit1, Johannes A Romijn2.   

Abstract

Paragangliomas (PGLs) are rare vascular, neuroendocrine tumors of paraganglia, which are associated with either sympathetic tissue in adrenal (pheochromocytomas (PCCs)) and extraadrenal (sympathetic paraganglioma (sPGLs)) locations or parasympathetic tissue of the head and neck paragangliomas (HNPGLs). As HNPGLs are usually benign and most tumors grow slowly, a wait-and-scan policy is often advised. However, their location in the close proximity to cranial nerves and vasculature may result in considerable morbidity due to compression or infiltration of the adjacent structures, necessitating balanced decisions between a wait-and-see policy and active treatment. The main treatment options for HNPGL are surgery and radiotherapy. In contrast to HNPGLs, the majority of sPGL/PCCs produces catecholamines, in advanced cases resulting in typical symptoms and signs such as palpitations, headache, diaphoresis, and hypertension. The state-of-the-art diagnosis and localization of sPGL/PCCs are based on measurement of plasma and/or 24-h urinary excretion of (fractionated) metanephrines and methoxytyramine (MT). sPGL/PCCs can subsequently be localized by anatomical (computed tomography and/or magnetic resonance imaging) and functional imaging studies (123I-metaiodobenzylguanidine-scintigraphy, 111In-pentetreotide scintigraphy, or positron emission tomography with radiolabeled dopamine or dihydroxyphenylalanine). Although most PGL/PCCs are benign, factors such as genetic background, tumor size, tumor location, and high MT levels are associated with higher rates of metastatic disease. Surgery is the only curative treatment. Treatment options for patients with metastatic disease are limited. PGL/PCCs have a strong genetic background, with at least one-third of all cases linked with germline mutations in 11 susceptibility genes. As genetic testing becomes more widely available, the diagnosis of PGL/PCCs will be made earlier due to routine screening of at-risk patients. Early detection of a familial PGL allows early detection of potentially malignant PGLs and early surgical treatment, reducing the complication rates of this operation.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2014        PMID: 25063320     DOI: 10.1530/EJE-14-0396

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

1.  Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy.

Authors:  Tsutomu Mizoshita; Masashi Ando; Hiroyuki Sagawa; Yoshinori Mori; Takahito Katano; Keiji Ozeki; Satoshi Tanida; Yasuyuki Okamoto; Takaya Shimura; Eiji Kubota; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Clin J Gastroenterol       Date:  2017-03-07

Review 2.  Factors affecting the haemodynamic behaviour of patients undergoing pheochromocytoma and paraganglioma removal: A review.

Authors:  Rashmi Ramachandran; Vimi Rewari
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

3.  A rare case of retroperitoneal paraganglioma located in the neck of the pancreas: a case report and literature review.

Authors:  Wenchao Wang; Yunsheng Qin; Huifang Zhang; Kangjie Chen; Zhengtao Liu; Shusen Zheng
Journal:  Gland Surg       Date:  2021-04

4.  A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.

Authors:  A Guha; Z Musil; A Vicha; T Zelinka; K Pacak; J Astl; M Chovanec
Journal:  Neoplasma       Date:  2019-06-29       Impact factor: 2.575

5.  Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.

Authors:  Yong Joon Suh; Ji-Young Choe; Hyo Jin Park
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

6.  Single-center study: dynamic contrast-enhanced ultrasound in the diagnostic assessment of carotid body tumors.

Authors:  Vincent Schwarze; Constantin Marschner; Giovanna Negrao De Figueiredo; Michael Ingrisch; Johannes Rübenthaler; Dirk-André Clevert
Journal:  Quant Imaging Med Surg       Date:  2020-09

7.  A Four-Generational Report on Hereditary Head and Neck Paraganglioma.

Authors:  Mihnea Cristian Trache; Julian Bewarder; Christian Stephan Betz; Nikolaus Möckelmann; Arne Böttcher
Journal:  Cureus       Date:  2022-04-14

8.  Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.

Authors:  Lei Zheng; Yalong Gu; Jiangcun Silang; Jinlong Wang; Feng Luo; Baopeng Zhang; Chuanhong Li; Feng Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

9.  Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature.

Authors:  Franz Sesti; Tiziana Feola; Giulia Puliani; Roberta Centello; Valentina Di Vito; Oreste Bagni; Andrea Lenzi; Andrea M Isidori; Vito Cantisani; Antongiulio Faggiano; Elisa Giannetta
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

10.  Re-evaluating the prevalence and factors characteristic of catecholamine secreting head and neck paragangliomas.

Authors:  Joshua D Smith; Susan E Ellsperman; Gregory J Basura; Tobias Else
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.